VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
INCY
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
INCYIncyte Corporation
$119.65$24.3B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
INCY logo

Incyte Corporation

INCY
NASDAQ · Oncology Biotech
$119.65
At close - Nov 6, 4:00 PM EST - USD
Market Cap$24.25B
P/E60.3x
52W High$132.60
Volume1.49M
OverviewTerminalAnalysisFinancialsValuationEarningsBreakoutsOwnership
VCP Research Verdict2026Q3

Diversified Growth Offsets Jakafi Patent Cliff Risk

Incyte's revenue reached roughly $1.6B in the latest quarter, up 14.0% year over year, with a Q2 2026 peak of $1.7B growing 37.7%, suggesting diversification beyond the legacy Jakafi franchise is gaining traction.

GrowthMixed
ProfitabilityStrained
ValuationExpensive
TechnicalsHealthy
Explore valuation models
MARKET ACTION

INCY price & volume

Price trend, volume and key moving averages

Launch Terminal
Loading chart...
Decision Checklist4 Core Signals

What matters now

The signals most likely to change the investment case.

01

Earnings momentum

6/12 Beats

EPS beat 6 of last 12 quarters

02

Valuation risk

+68% Peers

P/E is 68% above peer median

03

Market leadership

RS 75 · Avg

Average momentum (RS Rating: 75)

04

Healthy Uptrend

Uptrend

Price > 50DMA > 200DMA

Next CatalystEstimated earnings · Jan 29
01

Build the investment case

Start with the evidence for owning the stock and the risks that can break the thesis.

EXECUTIVE THESIS

The Investment Case

Full Analysis
Fundamental Trajectory

Revenue growth of 14.0% to roughly $1.6B and a stable 91.8%-93.7% gross margin suggest underlying product economics are sound, but operating margin swinging from -45.8% to 41.7% indicates that R&D intensity, with quarterly spend between $437.3M and $1.8B, remains the dominant driver of reported profitability.

Analyst Consensus+15.1% target
Buy(45 analysts)
24 Buy20 Hold1 Sell

The Bull Case

Upside Catalysts

Positive Phase 3 results

Incyte reported positive topline Phase 3 frontMIND results for tafasitamab (Monjuvi/Minjuvi) and lenalidomide combination, improving progression-free survival in high-risk diffuse large B-cell lymphoma.

Strong financial performance

Incyte's Q4 and full-year 2025 results showed revenue growth to US$1.51 billion and US$5.14 billion, respectively, with higher net income and earnings per share.

Opzelura growth potential

A bull case scenario suggests Opzelura adoption could accelerate dramatically, pushing annual revenue growth toward 10-12%.

The Bear Case

Key Downside Risks

Market performance

Price History →

Trailing total returns as of 11/7/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).

YTD Return
INCY+17.97%
S&P 500 (^GSPC)+7.63%
1-Year Return
INCY+13.74%
S&P 500 (^GSPC)+9.69%
3-Year Return
INCY+119.26%
S&P 500 (^GSPC)+71.31%
5-Year Return
INCY+79.95%
S&P 500 (^GSPC)+59.04%
02

Test the fundamentals

Check whether operating performance supports the current valuation.

VALUATION & INTRINSIC VALUE

Valuation Scenarios

Valuation Analysis
Trailing P/E5Y High
60.3x
Forward P/EExpansion
37.3x
EV/EBITDA80th %ile
26.8x
FCF YieldCash Flow
2.8%

Valuation vs 5-Year History

Multiple Range
Metric
Current
5Y Median
Historical Range
Percentile
P/E
60.3x
23.7x
80th· High
EV/EBITDA
26.8x
22.2x
80th· High
Price/FCF
35.4x
28.7x
80th· High
Current Multiple
5Y Median (50th %ile)

Intrinsic Value Scenarios

DCF Projection
Bear$58.44-51.2%
Base (Fair)$95.42-20.3%
Bull$119.40-0.2%
$58.44 Bear$95.42 Base$119.40 Bull
Current Market Price: $119.65
Trades at a 25.4% premium to Base DCF ($95.42)
Open DCF & Valuation Models →Chart Terminal ↗

Growth & profitability

Annual revenue & EPS trend
Revenue FY25
$5.14B+21.2% YoY
Net income FY25
$1.29B+3845.0% YoY
Free cash flow FY25
$1.35B+443.9% YoY
Operating margin FY25
26.1%+23.7 pts YoY
ROIC (FY25)51.1%
Avg ROIC 5Y28.2%
ROE (TTM)7.1%
Piotroski Score7 / 9
Financial Statements →
03

Monitor what changed

Recent results and news deserve attention only when they alter the forward view.

OPERATING RESULTS

Recent Earnings

Earnings History
EPS Beat Rate6/12 (50%)
Revenue Beat Rate8/12 (67%)
QuarterEPS (Act vs Est)Revenue (Act vs Est)
Q4 2026Latest
Oct 29, 2026
-$3.60+8.4%
vs -$3.93
$1.6B+6.3%
vs $1.5B
Q3 2026
Jul 28, 2026
$3.09+43.7%
vs $2.15
$1.7B+11.3%
vs $1.5B
Q2 2026
Apr 28, 2026
$1.81+35.1%
vs $1.34
$1.3B+4.7%
vs $1.2B
Q1 2026
Feb 10, 2026
$1.80-5.3%
vs $1.90
$1.5B+11.2%
vs $1.4B
Historical baseline: 12 quarters analyzedGAAP / Adjusted
MARKET COVERAGE

Latest News

4 Stories
Business Wire·1d ago
2026 Incyte Ingenuity Awards in GVHD™ Awarded to University of Maryland School of Medicine and H. Lee Moffitt Cancer Center & Research Institute

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte is proud to announce that the University of Maryland School of Medicine and H. Lee Moffitt Cancer Center & Research Institute have been selected as the recipients of the 2026 Incyte Ingenuity Awards in GVHD™. This annual award program recognizes and supports innovative projects that address the specific needs of individuals impacted by graft-versus-host disease (GVHD), including patients, caregivers and healthcare providers. “It is our honor to reco.

Defense World·2d ago
Incyte Corporation $INCY Shares Newly Purchased by Compass Financial Management LLC

Compass Financial Management LLC bought a new position in shares of Incyte Corporation (NASDAQ: INCY) in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 19,594 shares of the biopharmaceutical company's stock, valued at approximately $2,378,000. Other hedge

Defense World·4d ago
Aware Super Pty Ltd as trustee of Aware Super Sells 13,693 Shares of Incyte Corporation $INCY

Aware Super Pty Ltd as trustee of Aware Super lowered its position in Incyte Corporation (NASDAQ: INCY) by 4.5% during the undefined quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 293,117 shares of the biopharmaceutical company's stock after selling 13,693 shares during the

24/7 Wall Street·Oct 30, 2026
Buy, Sell, or Hold? Today's Top Upgrades and Downgrades: Boston Scientific, DoorDash, GE Vernova, Honeywell Aerospace, Incyte.

Pre-Market Stock Futures: Futures are trading lower this Friday, with the Nasdaq down almost 2.

Filtered for Incyte CorporationMore Headlines
04

Compare before deciding

Benchmark INCY against direct peers instead of judging its metrics in isolation.

Peers Comparison

Key metrics vs top competitors for Incyte Corporation (INCY)

Full Screener →
CompanyPriceMarket CapP/E RatioRev Growth (1Y)Net MarginROEDiv Yield
INCY logoINCYIncyte CorporationCurrent
$119.65$24.25B60.2821.22%6.71%7.11%—
ALKS logoALKSAlkermes plc
$45.90$7.7B-9999.00-5.25%-0.02%-0.02%—
JAZZ logoJAZZJazz Pharmaceuticals plc
$234.76$14.75B73.754.88%4.37%4.62%—
EXEL logoEXELExelixis, Inc.
$69.57$17.49B20.106.98%35.45%45.54%—
HALO logoHALOHalozyme Therapeutics, Inc.
$103.63$12.29B26.1837.55%26.93%544.26%—
IONS logoIONSIonis Pharmaceuticals, Inc.
$39.42$6.55B-11.5533.87%-64.64%-110.84%—

Compare INCY vs Peers

Incyte Corporation (INCY) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs ALKS

Most directly comparable listed peer for INCY.

Scale Benchmark

vs LLY

Larger-name benchmark to compare INCY against a more recognizable public peer.

Peer Set

Compare Top 5

vs ALKS, JAZZ, EXEL, HALO

05

Keep researching

Verify the primary filings, follow material updates, and answer the remaining questions.

INCY SEC Filings & Documents

Incyte Corporation (INCY) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

6
Material company update

Oct 29, 2026·SEC

Material company update

Jul 28, 2026·SEC

Material company update

Jul 6, 2026·SEC

10-K Annual Reports

2
FY 2026

Feb 10, 2026·SEC

FY 2025

Feb 10, 2025·SEC

10-Q Quarterly Reports

6
FY 2026

Oct 29, 2026·SEC

FY 2026

Jul 28, 2026·SEC

FY 2026

Apr 28, 2026·SEC

Get notified when INCY posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

INCY Frequently Asked Questions

Incyte Corporation (INCY) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials
What is Incyte Corporation's revenue?

Incyte Corporation (INCY) reported $6.01B in revenue over the trailing twelve months. Revenue was $5.14B in fiscal year 2025. That is 12170% more than the $41.9M of fiscal year 1996.

How fast is Incyte Corporation growing?

Incyte Corporation (INCY) grew revenue by 24.9% over the trailing twelve months, compared with the twelve months before.

Is INCY profitable?

Yes. Incyte Corporation (INCY) earned $403.4M in net income over the trailing twelve months (a 6.7% net margin).

Dividend & Returns
What is INCY's return on equity?

Incyte Corporation (INCY) had a return on equity (ROE) of 7.1% over the trailing twelve months. That is below the market's typical 10-15%.

What is Incyte Corporation's free cash flow?

Incyte Corporation (INCY) generated $684.9M in free cash flow over the trailing twelve months.

What if you invested $1,000 in INCY back in 1996?

Total return calculator · dividends reinvested · 30+ years of data

See returns →